Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective an…
Toya T; Mizuno K; Sakurai M; Kato J; Mori T; Doki N; Masuda S; Aotsuka N; Tsukamoto S; Sakaida E; Nakajima Y; Fujisawa S; Machida S; Aoyama Y; Yokoyama H; Shono K; Hatta Y; Usuki K; Kataoka K; Kanda Y.
Blood Adv
(Unknown)
Published: 2024
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Short NJ; Jabbour E; Jain N; Senapati J; Nasr L; Haddad FG; Li Z; Hsiao YC; Yang JJ; Pemmaraju N; Ohanian M; Wierda WG; Montalban-Bravo G; Borthakur G; Han L; Xiao L; Huang X; Abramova R; Zhao M; Garris R; Konopleva M; Ravandi F; Kantarjian H.
Blood Adv
(Unknown)
Published: 2024
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study.
Pagani C; Rusconi C; Dalla Pria A; Ravano E; Schommers P; Bastos-Oreiro M; Verga L; Gini G; Spina M; Arcaini L; Steffanoni S; Dalu D; Crucitti L; Lorenzi L; Balzarini P; Cattaneo C; Bongiovanni L; Rosenwald A; Facchetti F; Bower M; Ferreri AJM; Rossi G; Tucci A; Re A.
Blood Adv
(Unknown)
Published: 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for hig…
Garcia JS; Kim HT; Murdock HM; Ansuinelli M; Brock J; Cutler CS; Gooptu M; Ho VT; Koreth J; Nikiforow S; Romee R; Shapiro R; DeAngelo DJ; Stone RM; Bat-Erdene D; Ryan J; Contreras ME; Fell G; Letai A; Ritz J; Lindsley RC; Soiffer RJ; Antin JH.
Blood Adv
(Unknown)
Published: 2024
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial.
Bhattacharya R; Uddin MM; Patel AP; Niroula A; Finneran P; Bernardo R; Fitch KV; Lu MT; Bloomfield GS; Malvestutto C; Aberg JA; Fichtenbaum CJ; Hornsby W; Ribaudo HJ; Libby P; Ebert BL; Zanni MV; Douglas PS; Grinspoon SK; Natarajan P.
Blood Adv
(Unknown)
Published: 2024
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.
de Jonge AV; Duetz C; Bruins WSC; Korst CLBM; Rentenaar R; Cosovic M; Eken M; Twickler I; Nijland M; van der Poel MWM; de Heer K; Klerk CPW; Strobbe L; Oosterveld M; Boersma R; Koene HR; Roemer MGM; van Werkhoven E; Chamuleau MED; Mutis T.
Blood Adv
(Unknown)
Published: 2024
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
Herling M; Dearden C; Zaja F; El-Sharkawi D; Ding W; Bellido M; Khot A; Tick L; Jacobsen E; Eyre TA; Roos-Weil D; Kadia T; Lucchini E; Pflug N; Davids MS; Pena G; Mukherjee N; Badawi M; Vizkelety T; Staber PB.
Blood Adv
(Unknown)
Published: 2024
CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model.
Neidemire-Colley L; Khanal S; Braunreiter KM; Gao Y; Kumar R; Snyder KJ; Weber MA; Surana S; Toirov O; Karunasiri M; Duszynski ME; Chi M; Malik P; Kalyan S; Chan WK; Naeimi Kararoudi M; Choe HK; Garzon R; Ranganathan P.
Blood Adv
(Unknown)
Published: 2024
The intrinsic coagulation pathway plays a dominant role in driving hypercoagulability in ANCA-associated vasculitis.
Busch MH; Ysermans R; Aendekerk JP; Timmermans SAMEG; Potjewijd J; Damoiseaux JGMC; Spronk HMH; Ten Cate H; Reutelingsperger CP; Nagy M; van Paassen P.
Blood Adv
(Unknown)
Published: 2024
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.
Chan O; Al Ali N; Tashkandi H; Ellis A; Ball S; Grenet J; Hana C; Deutsch Y; Zhang L; Hussaini M; Song J; Yun S; Talati C; Kuykendall A; Padron E; Walker A; Roboz G; Desai P; Sallman D; Sweet K; Komrokji R; Lancet J.
Blood Adv
(Unknown)
Published: 2024
Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drug-induced thromboembolism.
Hatakeyama K; Kikushige Y; Ishihara D; Yamamoto S; Kawano G; Tochigi T; Miyamoto T; Sakoda T; Christoforou A; Kunisaki Y; Fukata M; Kato K; Ito T; Handa H; Akashi K.
Blood Adv
(Unknown)
Published: 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therap…
Ahn IE; Brander DM; Ren Y; Zhou Y; Tyekucheva S; Walker HA; Black R; Montegaard J; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng SY; Crombie J; Fisher DC; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Brown JR; Davids MS.
Blood Adv
(Unknown)
Published: 2024
Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas.
Shukla ND; Schroers-Martin JG; Sworder BJ; Kathuria KR; Alig SK; Frank MJ; Miklos DB; Coutre S; Diehn M; Khodadoust MS; Roschewski M; Kurtz DM; Alizadeh AA.
Blood Adv
(Unknown)
Published: 2024
High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer.
Stonestrom AJ; Menghrajani KN; Devlin SM; Franch-Expósito S; Ptashkin RN; Patel SY; Spitzer B; Wu X; Jee J; Sánchez Vela P; Milbank JH; Shah RH; Mohanty AS; Brannon AR; Xiao W; Berger MF; Mantha S; Levine RL.
Blood Adv
(Unknown)
Published: 2024
Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation.
Fuchs SNR; Stalmann USA; Snoeren IAM; Bindels E; Schmitz S; Banjanin B; Hoogenboezem RM; van Herk S; Saad M; Walter W; Haferlach T; Seillier L; Saez-Rodriguez J; Dugourd AJF; Lehmann KV; Ben-Neriah Y; Gleitz HFE; Schneider RK.
Blood Adv
(Unknown)
Published: 2024